Joseph Kurth, MD
Family Medicine · Sioux City, IANPI 1093911372
Payments from drug & device makers
Across 227 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$739
- Aimmune Therapeutics, Inc.$403
- Pfizer$402
- Amgen$383
- Novo Nordisk$288
- AstraZeneca$158
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,782100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $739 |
| Aimmune Therapeutics, Inc. | 2 | $403 |
| Pfizer | 31 | $402 |
| Amgen(2 entities) | 25 | $383 |
| Novo Nordisk | 20 | $288 |
| AstraZeneca | 9 | $158 |
| Astellas Pharma US Inc | 9 | $130 |
| Nestle Healthcare Nutrition Inc. | 2 | $117 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $103 |
| Otsuka America Pharmaceutical, Inc. | 6 | $102 |
| Pacira Therapeutics, Inc. | 3 | $89 |
| Boehringer Ingelheim | 6 | $84 |
| Bayer | 5 | $69 |
| Lilly USA, LLC | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| GSK | 4 | $51 |
| Merck | 3 | $41 |
| Verona Pharma, Inc. | 2 | $41 |
| Corium, LLC | 4 | $41 |
| Alkermes, Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Abbott | 2 | $33 |
| Mylan Specialty L.p. | 2 | $29 |
| Novartis | 2 | $29 |
| Genentech USA, Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $23 |
| Lundbeck LLC | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZENPEP$408
How this compares
$3,798 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $90,403 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $73,698 |
| OzempicSemaglutide | 41 | $39,962 |
| JanuviaSitagliptin Phosphate | 45 | $33,286 |
| ProliaDenosumab | 17 | $29,612 |
| MounjaroTirzepatide | 27 | $28,031 |
| JardianceEmpagliflozin | 31 | $23,094 |
| RybelsusSemaglutide | 13 | $22,510 |
| MyrbetriqMirabegron | 34 | $18,511 |
| TradjentaLinagliptin | 28 | $17,456 |
| FarxigaDapagliflozin Propanediol | 19 | $14,408 |
| XareltoRivaroxaban | 12 | $13,799 |
| TrulicityDulaglutide | 11 | $12,760 |
| Spiriva HandihalerTiotropium Bromide | 21 | $12,646 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $12,423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Prempro, Paxlovid | $402 | $97,665165 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $51 | $94,908143 claims |
| Novo NordiskOzempic, Rybelsus | $288 | $62,47254 claims |
| Lilly USA, LLCMounjaro, Trulicity | $62 | $40,79138 claims |
| Boehringer IngelheimJardiance, Tradjenta | $84 | $40,55159 claims |
| MerckJanuvia | $41 | $33,28645 claims |
| AmgenProlia | $383 | $29,61217 claims |
| Astellas Pharma US IncMyrbetriq | $130 | $18,51134 claims |
| AstraZenecaFarxiga | $158 | $14,40819 claims |
| Johnson & JohnsonXarelto | $14 | $13,79912 claims |
| AbbVieSynthroid | $739 | $3,25938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Sioux City
- Nicholas BechtoldSioux City$584K
- Frank MarinoSioux City$8K
- Paul PetersonSioux City$8K
- Jeffrey KrohnSioux City$7K
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.